RAPP — Rapport Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2012593 ·
Last close
$49.33
Market Cap
$2.37B
52W High
$50.25
52W Low
$33.51
ADV30
292,174
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -60,806,000 | -56,615,000 | 458,982,000 | 63,612,000 | 36,056,000 |
| Mar 2026 | 20,000,000 | — | -24,215,000 | -19,857,000 | 497,597,000 | 78,056,000 | 26,085,000 |
| Dec 2025 | 0 | — | -38,509,000 | -33,763,000 | 512,431,000 | 52,645,000 | 27,778,000 |
| Sep 2025 | 0 | — | -29,986,000 | -26,925,000 | 535,323,000 | 251,359,000 | 23,706,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-96,682,000
Investing CF
$-167,559,000
Financing CF
$272,786,000
CapEx
$-467,000
Dividends Paid
—
Buybacks
$-5,000
EPS Diluted TTM
$-3.04
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-311,700,000
Inventory
—
Receivables
$293,000
ST Investments
$372,465,000
EBIT TTM
$-153,516,000
Pretax Income TTM
$-137,160,000
Interest Exp TTM
—
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$20,000,000
EBITDA
$-152,556,000
Free Cash Flow
$-56,016,500
Enterprise Value
$1,940,796,800
Total Cash
$436,076,992
Total Debt
$10,105,000
Shares Out
47,978,286
Trailing EPS
$-3.11
Book Value
$8.82
ROE
-40.0%
ROA
-25.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -125,099,000 | -111,483,000 | 512,431,000 | 27,778,000 | — | -87,473,000 |
| Dec 2024 | 0 | -83,055,000 | -78,307,000 | 314,933,000 | 9,506,000 | — | -64,828,000 |
| Dec 2023 | 0 | -36,179,000 | -34,786,000 | 155,423,000 | 181,057,000 | — | -27,181,000 |
| Dec 2022 | — | — | — | 31,603,000 | 41,665,000 | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.23
Max Pain — expiry 2026-12-18
max pain strike: $40.00 · spot: $49.33 · call oi: 2,162 · put oi: 839Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NUVB | Nuvation Bio Inc. | $2.37B | $6.76 | — |
| OCUL | OCULAR THERAPEUTIX, INC | $2.37B | $10.78 | — |
| VERA | Vera Therapeutics, Inc. | $2.43B | $33.72 | — |
| GIFOF | Grifols SA | $2.29B | $8.85 | — |
| GENB | Generate Biomedicines, Inc. | $2.27B | $17.72 | — |
News headlines (Yahoo Finance, 1h cache)
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
2026-08-24 11:00 · Yahoo
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
2026-08-05 11:00 · Yahoo
What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors?
2026-07-12 23:53 · Yahoo
Is Rapport Therapeutics (RAPP) Using RAP-219 To Redefine Its Broader Neuroscience Investment Narrative?
2026-06-08 02:08 · Yahoo
BTIG Raises its Price Target on Rapport Therapeutics (RAPP)
2026-06-05 21:03 · Yahoo
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
2026-05-20 20:05 · Yahoo
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss
2026-05-07 12:50 · Yahoo
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
2026-05-07 11:00 · Yahoo
Rapport Therapeutics Insiders Added US$1.61m Of Stock To Their Holdings
2026-04-30 13:04 · Yahoo
Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near
2026-04-27 20:17 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.